Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

This phase 3 PERSEUS trial evaluated subcutaneous daratumumab added to bortezomib, lenalidomide, and dexamethasone (D VRd) versus VRd alone in transplantation eligible patients with newly diagnosed multiple myeloma. Among 709 patients, D VRd significantly improved progression free survival (84.3% vs. 67.7% at 48 months; HR 0.42, P<0.001), complete response rates (87.9% vs. 70.1%), and minimal residual disease (MRD) negative status (75.2% vs. 47.5%). Safety profiles were consistent with known regimens, though neutropenia and thrombocytopenia were more frequent in the D VRd group. These findings support D VRd as a new standard of care for eligible patients.

This phase 3 PERSEUS trial evaluated subcutaneous daratumumab added to bortezomib, lenalidomide, and dexamethasone (D VRd) versus VRd alone in transplantation eligible patients with newly diagnosed multiple myeloma. Among 709 patients, D VRd significantly improved progression free survival (84.3% vs. 67.7% at 48 months; HR 0.42, P<0.001), complete response rates (87.9% vs. 70.1%), and minimal residual disease (MRD) negative status (75.2% vs. 47.5%). Safety profiles were consistent with known regimens, though neutropenia and thrombocytopenia were more frequent in the D VRd group. These findings support D VRd as a new standard of care for eligible patients.